Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 8/2013

01-08-2013 | VASCULITIS (LR ESPINOZA, SECTION EDITOR)

IgG4-Associated Vasculitis

Authors: Rodolfo Perez Alamino, Carlos Martínez, Luis R. Espinoza

Published in: Current Rheumatology Reports | Issue 8/2013

Login to get access

Abstract

Elevated IgG4 is characteristic of cases of IgG4-RD, a newly recognized systemic disease. However, several chronic inflammatory conditions, including rheumatic diseases, can also be associated with increased levels of IgG4. There have also recently been several reports describing an increased IgG4 immune response to some vasculitis syndromes, in particular Churg–Strauss syndrome and granulomatosis with polyangiitis. To avoid misdiagnosis, clinicians must be aware that the clinical manifestations of IgG4-RD and ANCA-associated vasculitis may overlap. The meaning of these observations is not yet understood, and more studies are needed to determine the true significance of the increased IgG4 response to vasculitis syndromes, especially anti-neutrophil cytoplasmatic antibodies (ANCA)-associated vasculitis.
Literature
1.
Aucouturier A, Danon F, Daveau M, et al. Measurement of serum IgG4 levels by a competitive immunoenzymatic assay with monoclonal antibodies. J Immunol Methods. 1984;74:151–62.PubMedCrossRef
2.
• Nirula A, Glaser SM, Kalled SL, et al. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol. 2011;23:119–24. Comprehensive review of the biological characteristics of IgG4 antibody and its proposed effect in immunological diseases.PubMedCrossRef
3.
Aalberse RC, Van Milligen F, Tan KY, et al. Allergen-specific IgG4 in atopic disease. Allergy. 1993;48:559–69.PubMedCrossRef
4.
Hussain R, Poindexter R, Ottesen E. Control of allergic reactivity in human filariasis: predominant localization of blocking antibody to the IgG4 subclass. J Immunol. 1992;2731–7.
5.
Kanari H, Kagami S, Kashiwakuma D, et al. Role of Th2 cells in IgG4-related lacrimal gland enlargement. Int Arch Allergy Immunol. 2010;152 Suppl 1:47–53.PubMedCrossRef
6.
Suzuki K, Tamaru J, Okuyama A, et al. IgG-4 positive multiorgan lymphoproliferative syndrome manifesting as chronic symmetrical sclerosing dacryo-sialadenitis with subsequent secondary portal hypertension and remarkable IgG4-linked IL-4 elevation. Rheumatology (Oxford). 2010;49:1789–91.CrossRef
7.
Kamisawa T, Anjiki H, Egawa N, et al. Allergic manifestations in autoimmune pancreatitis. Eur J Gastroenterol Hepatol. 2009;21:1136–9.PubMedCrossRef
8.
9.
Rispens T, Ooijevaar-De Heer P, Vermeulen E, et al. Human IgG4 binds to IgG4 and conformationally altered IgG1 via Fc–Fc interactions. J Immunol. 2009;182:4275–81.PubMedCrossRef
10.
Van der NeutKolfschoten M, Schuurman J, Losen M, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab-arm exchange. Science. 2007;317:1554–7.CrossRef
11.
Stone J, Khosroshahi A, Deshpande V, et al. Recommendations for the Nomenclature of IgG4-Related Disease and its individual organ system manifestations. Arthritis Rheum. 2012;64:3061–7.PubMedCrossRef
12.
•• Stone J, Zen Y, Deshpande V. IgG4-Related Disease. N Engl J Med. 2012;366:539–51. A very good description of clinical, pathological and radiological features of IgG4-RD, with a current therapeutic approach.PubMedCrossRef
13.
Deshpande V, Zen Y, Chan J, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25:1181–92.PubMedCrossRef
14.
Zen Y, Nakanuma Y. IgG4-Related Disease. A cross-sectional study of 114 patients. Am J Surg Pathol. 2010;34:1812–9.PubMedCrossRef
15.
Lin G, Li J. Elevation of serum IgG subclass concentration in patients with rheumatoid arthritis. Rheumatol Int. 2010;30:837–40.PubMedCrossRef
16.
Strehl J, Hartmann A, Agaimy A. Numerous IgG4-positive plasma cells are ubiquitous in diverse localised non-specific chronic inflammatory conditions and need to be distinguished from IgG4-related systemic disorders. J Clin Pathol. 2011;64:237–43.PubMedCrossRef
17.
Churg J, Strauss L. Allergic granulomatosis angiitis and periarteritis nodosa. Am J Pathol. 1951;27:277–94.PubMed
18.
• Vaglio A, Buzio C, Zwerina J. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss): state of the art. Allergy. 2013;68:261–73. Excellent overview of EGPA, particularly focusing on recent advances in pathogenesis, diagnosis, and treatment.PubMedCrossRef
19.
Zwerina J, Bach C, Martorana D, et al. Eotaxin-3 in Churg Strauss syndrome: a clinical and immunogenetic study. Rheumatology (Oxford). 2011;50:1823–7.CrossRef
20.
Bottero P, Bonini M, Vecchio F, et al. The common allergens in the Churg–Strauss syndrome. Allergy. 2007;62:1288–94.PubMedCrossRef
21.
Yamamoto M, Takahashi H, Suzuki C, et al. Analysis of serum IgG subclasses in Churg–Strauss syndrome: the meaning of elevated serum levels of IgG4. Intern Med. 2010;49:1365–70.PubMedCrossRef
22.
Yamamoto M, Tabeya T, Naishiro Y, et al. Value of serum IgG4 in the diagnosis of IgG4-related disease and in differentiation from rheumatic diseases and other diseases. Mod Rheumatol. 2012;22(3):419–25.PubMedCrossRef
23.
•• Vaglio A, Strehl JD, Manger B, et al. IgG4 immune response in Churg–Strauss syndrome. Ann Rheum Dis. 2012;71:390–3. Comprehensive report and literature review of increased serum levels of IgG4 in patients with Churg–Strauss syndrome.PubMedCrossRef
24.
Ayuzawa N, Ubara Y, Keiichi S, et al. Churg–Strauss syndrome with a clinical condition similar to IgG4-related kidney disease: a case report. Intern Med. 2012;51:1233–8.PubMed
25.
• Ryu J, Horie R, Sekiguchi H, et al. Spectrum of disorders associated with elevated serum IgG4 levels in clinical practice. Int J Rheumatol. 2012;vol 2012, Article ID 232960; 6 pages. Interesting study focusing on the frequency of IgG4-RD and other disease associations in patients with elevated serum IgG4 levels.
26.
27.
Yi ES, Colby T. Wegener’s granulomatosis. Semin Diag Pathol. 2001;18(1):34–46.
28.
Kalina P, Lie J, Campbell R, et al. Diagnostic value and limitations of orbital biopsy in Wegener’s granulomatosis. Ophthalmol. 1992;99(1):120–4.
29.
•• Chang S, Keogh K, Lewis J, et al. Increased IgG4-positive plasma cells in granulamotosis with polyangiitis: a diagnostic pitfall of IgG4-related disease. Int J Rheumatol. 2012;vol 2012, Article ID 121702, 6 pages. This study investigates the prevalence of IgG4 + plasma cells in patients with diagnosis of GPA, suggesting that GPA should be included in the differential diagnosis of IgG4-RD.
30.
Ebbo M, Grados A, Bernit E, et al. Pathologies associated with serum IgG4 elevation. Int J Rheumatol. 2012;vol 2012, Article ID 602809, 6 pages.
31.
Brouwer E, Tervaert JW, Horst G, et al. Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmatic autoantibodies (ANCA) in patients with Wegener’s granulomatosis and clinically related disorders. Clin Exp Immunol. 1991;83:379–86.PubMedCrossRef
32.
Holland M, Hewins P, Goodall M, et al. Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener’s granulomatosis: a possible pathogenic role for the IgG4 subclass. Clin Exp Immunol. 2004;138:183–92.PubMedCrossRef
33.
Liu L, Chen M, Yu F, et al. IgG subclass distribution, affinity of anti-myeloperoxidase antibodies in sera from patients with Wegener’s granulomatosis and microscopic polyangiitis. Nephrology. 2008;13:629–35.PubMedCrossRef
34.
Wakamatsu R, Watanabe H, Suzuki K, et al. Hypocomplementemic urticarial vasculitis syndrome is associated with high levels of serum IgG4: a clinical manifestation that mimics IgG4-related disease. Intern Med. 2011;50:1109–12.PubMedCrossRef
35.
Tamai R, Hasegawa Y, Hisano S, et al. A case of IgG4-related tubulointerstitial nephritis concurrent with Henoch–Schönlein purpura nephritis. Allergy Asthma Clin Immunol. 2011;7:5.PubMedCrossRef
36.
Metadata
Title
IgG4-Associated Vasculitis
Authors
Rodolfo Perez Alamino
Carlos Martínez
Luis R. Espinoza
Publication date
01-08-2013
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 8/2013
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-013-0348-9

Other articles of this Issue 8/2013

Current Rheumatology Reports 8/2013 Go to the issue

OSTEOARTHRITIS (MB GOLDRING, SECTION EDITOR)

Genetically Engineered Mouse Models Reveal the Importance of Proteases as Osteoarthritis Drug Targets

INFLAMMATORY MUSCLE DISEASE (I LUNDBERG, SECTION EDITOR)

Clinical Heterogeneity and Outcomes of Antisynthetase Syndrome

SERONEGATIVE ARTHRITIS (MA KHAN, SECTION EDITOR)

Spondyloarthritis Associated with Acne Conglobata, Hidradenitis Suppurativa and Dissecting Cellulitis of the Scalp: A Review with Illustrative Cases

SERONEGATIVE ARTHRITIS (MA KHAN, SECTION EDITOR)

Ankylosing Spondylitis: Chinese Perspective, Clinical Phenotypes, and Associated Extra-articular Systemic Features

SERONEGATIVE ARTHRITIS (MA KHAN, SECTION EDITOR)

Advances and Challenges in Spondyloarthritis Imaging for Diagnosis and Assessment of Disease

SERONEGATIVE ARTHRITIS (MA KHAN, SECTION EDITOR)

Advances in the Genetics of Spondyloarthritis and Clinical Implications
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits